Lably
Skip to content

Explore on Lably

ToursExplore Lably’s 3D tours

The purpose of a colonoscopy is to inspect the internal lining of the colon wall, to detect ulceration or precancerous polyps, and to permit biopsy or removal of suspected colorectal cancer lesions.

Colonoscopy surveys the entire colon, which runs 120 to 150 cm (4–5 ft). Sigmoidoscopy is similar, but only surveys the sigmoid colon, which comprises 60 cm of the distal (left) side of the colon. The benefits of colonoscopy for cancer survival have primarily been associated with the detection of lesions in the distal portion of the colon.

Routine use of colonoscopy screening varies globally. In the US, colonoscopy is a commonly recommended and widely utilized screening method for colorectal cancer, often beginning at age 45 or 50, depending on risk factors and guidelines from organizations like the American Cancer Society. However, in the European Union, several countries primarily employ fecal occult blood testing (FOBT) or sigmoidoscopy for population-based screening. These variations stem from many factors. Recent studies have stressed the need for screening strategies and awareness campaigns to combat colorectal cancer - on a global scale.

Research is underway to identify the characteristics of patients that may indicate potential difficulties in performing a colonoscopy in a given individual, both in children and adults.

Medical uses

Conditions that call for colonoscopies include gastrointestinal hemorrhage, unexplained changes in bowel habit and suspicion of malignancy. Colonoscopies are often used to diagnose colon polyp and colon cancer, but are also frequently used to diagnose inflammatory bowel disease.

Fecal occult blood is a quick test which can be done to test for microscopic traces of blood in the stool. A positive test is almost always an indication to do a colonoscopy. In most cases the positive result is just due to hemorrhoids; however, it can also be due to diverticulosis, inflammatory bowel disease (Crohn's disease, ulcerative colitis), colon cancer, or polyps. Colonic polypectomy has become a routine part of colonoscopy, allowing quick and simple removal of polyps during the procedure, without invasive surgery.

Occasional rectal bleeding may have multiple non-serious potential causes.

Colon cancer screening

Colonoscopy is one of the colorectal cancer screening tests recommended to people in the US who are 45 to 75 years of age. The other screening tests are flexible sigmoidoscopy, double-contrast barium enema, computed tomographic (CT) colonography (virtual colonoscopy), guaiac-based fecal occult blood test (gFOBT), fecal immunochemical test (FIT), and multitarget stool DNA screening test (Cologuard).

Subsequent rescreenings are scheduled based on the initial results found, with a ten-year recall being common for colonoscopies that produce normal results.

Among people who have had an initial colonoscopy that found no polyps, the risk of developing colorectal cancer within five years is extremely low. Therefore, the risks of the procedure outweigh the benefits of having another colonoscopy sooner than five years after the first screening.

Some medical societies in the US recommend a screening colonoscopy every ten years beginning at age 50 for adults without increased risk for colorectal cancer. Research shows that the risk of cancer is low for 10 years if a high-quality colonoscopy does not detect cancer, so tests for this purpose are indicated every ten years.

Colonoscopy screening is associated with approximately two-thirds fewer deaths due to colorectal cancers on the left side of the colon, and is not associated with a significant reduction in deaths from right-sided disease. It is speculated that colonoscopy might reduce rates of death from colon cancer by detecting some colon polyps and cancers on the left side of the colon early enough that they may be treated, and a smaller number on the right side.

Since polyps often take 10 to 15 years to transform into cancer in someone at average risk of colorectal cancer, guidelines recommend 10 years after a normal screening colonoscopy before the next colonoscopy. (This interval does not apply to people at high risk of colorectal cancer or those who experience symptoms of the disease.)

The large randomized pragmatic clinical trial NordICC was the first published trial on the use of colonoscopy as a screening test to prevent colorectal cancer, related death, and death from any cause. It included 84,585 healthy men and women aged 55 to 64 years in Poland, Norway, and Sweden, who were randomized to either receive an invitation to undergo a single screening colonoscopy (invited group) or to receive no invitation or screening (usual-care group). Of the 28,220 people in the invited group, 11,843 (42.0%) underwent screening. A total of 15 people who underwent colonoscopy (0.13%) had major bleeding after polyp removal.

None of the participants experienced a colon perforation due to colonoscopy. After 10 years, an intention-to-screen analysis showed a significant relative risk reduction of 18% in the risk of colorectal cancer (0.98% in the invited group vs. 1.20% in the usual-care group). The analysis showed no significant change in the risk of death from colorectal cancer (0.28% vs. 0.31%) or in the risk of death from any cause (11.03% vs. 11.04%). To prevent one case of colorectal cancer, 455 invitations to colonoscopy were required.

As of 2026, the CONFIRM trial, a randomized trial evaluating colonoscopy vs. fecal immunochemical test is currently ongoing. This study includes 50,126 military veterans, mostly males, in the US with follow up planned through 2028.

In 2021, the US spent $43 billion on cancer screening to prevent five types of cancer, with colonoscopies accounting for 55% of the total. The death rate from colon cancer has been on a linear decline for 40 years, falling by nearly 50 percent from the 1980s (when few were screened) to 2024; however, the increase in screening did not accelerate the decline. Therefore, resources devoted to cancer screening would be better directed toward ensuring widespread access to effective cancer treatment.

Recommendations

The American Cancer Society issues recommendations on colorectal cancer screening guidelines. These guidelines often change and are updated as new studies and technologies have become available

Many other national organizations also issue such guidance, such as the UK's NHS and various European agencies, guidance can vary between such agencies.

Medicare coverage

In the United States, Medicare insurance covers a number of colorectal-cancer screening tests.

Sign in to keep reading

5 more chapters are free with a Lably account.

More in Health